Takeaways Médunik Canada’s exclusive distribution of Increlex (mecasermin) with ESTEVE ensures that children and adolescents with severe primary IGF‑1 deficiency in Canada can con...
Takeaways Health Canada’s approval of Novartis’ Vanrafia (atrasentan) creates Canada’s first endothelin receptor antagonist–based therapy specifically for IgA nephropathy, giving clini...
Takeaways The Canadian NOC formally moves Scenesse from special‑access cases to on‑label, publicly or privately reimbursed treatment for erythropoietic protoporphyria, e...
Takeaways The Teva Canada–Samsung Bioepis deal makes Opuviz (aflibercept biosimilar to Eylea) a commercially available, lower‑cost alternative in Canada’s wet AMD, DME, and retinal vein occlusio...
Takeaways Sobi’s Empaveli is now positioned to move from import‑only, limited‑access status into publicly funded, pan‑Canadian treatment for C3 glomerulopathy and primary IC‑MPGN, one ...
Takeaways Ebglyss is now positioned to move from province‑specific coverage into broad, pan-Canadian reimbursement, which should materially expand Lilly’s eczema market and patient access. ...
Takeaways: Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicl...
Takeaways: Cipher’s pCPA LOI for Epuris is a market inflection point that should expand revenue and prescription volume by shifting isotretinoin from patchy, private-pay cove...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
Takeaways: The new products expand Organon’s Canadian biosimilars line to eight drugs across five therapeutic areas, including oncology, strengthening its position as a major biosimilar sup...
